FHAM
ALXN

Folger Hill Asset Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Folger Hill Asset Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-50,000
Closed -$5.84M – 295
2016
Q2 		$5.84M Buy
+50,000
New +$7.09M 0.46% 78

Other funds holding ALXN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Folger Hill Asset Management's ALXN Position: Q3 2017 in Review

Folger Hill Asset Management sold out of Alexion Pharmaceuticals (ALXN) in Q3 2017, closing a stake of 75,019 shares — an estimated $9.13M sold.

Folger Hill Asset Management first reported a position in ALXN in Q4 2015 and held it in 6 quarters. The position peaked at $9.13M in Q2 2017. 595 funds tracked by Wall St. Rank hold ALXN as of Q3 2017.

  • Folger Hill Asset Management reported no remaining Alexion Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
  • Folger Hill Asset Management sold 75,019 Alexion Pharmaceuticals shares in Q3 2017, an estimated $9.13M.
  • Folger Hill Asset Management first reported a position in Alexion Pharmaceuticals in Q4 2015 and held it in 6 quarters.
  • Folger Hill Asset Management's Alexion Pharmaceuticals position peaked at $9.13M in Q2 2017.
  • 595 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2017.

Based on Folger Hill Asset Management's 13F filing for Q3 2017, filed 14 Nov 2017.